Capmatinib with Sulfasalazine Interaction Details
Brand Names Associated with Capmatinib
- Capmatinib
- Tabrecta®
Brand Names Associated with Sulfasalazine
- Azulfidine®
- Azulfidine® EN-tabs®
- Sulfasalazine
Medical Content Editor Dr. Brian Staiger, PharmD
Last updated
Dec 18, 2023
Interaction Effect
Increased BCRP substrate exposure and an increased risk of adverse reactions
Interaction Summary
Coadministration of capmatinib with a BCRP substrate increased BCRP substrate exposure, which may increase the adverse reactions of these substrates. When coadministered with rosuvastatin, the AUC(0 to infinity) of rosuvastatin increased by 108% and Cmax increased by 204% . If coadministration is unavoidable between capmatinib and BCRP substrates where minimal concentration changes may lead to serious adverse reactions, decrease the BCRP substrate dosage as recommended .
Severity
Major
Onset
Unspecified
Evidence
Probable
How To Manage Interaction
Coadministration of capmatinib with a BCRP substrate increased BCRP substrate exposure, which may increase the adverse reactions of these substrates. If coadministration is unavoidable between capmatinib and BCRP substrates where minimal concentration changes may lead to serious adverse reactions, decrease the BCRP substrate dosage as recommended.
Mechanism Of Interaction
Inhibition of BCPR-mediated efflux transport of BCRP substrate
Literature Reports
A) Coadministration of capmatinib with rosuvastatin (a BCRP substrate) increased rosuvastatin AUC(0 to infinity) by 108% and increased Cmax by 204% . Compared with rosuvastatin alone, the rosuvastatin geometric mean ratio for AUC(infinity) was 2.08 (90% CI, 1.56 to 2.76), AUC(last) was 2.03 (90% CI, 1.61 to 2.56), and Cmax was 3.04 (90% CI, 2.36 to 3.92) following coadministration of capmatinib and rosuvastatin in a small prospective single-sequence study in adult patients with MET-dysregulated advanced solid tumors refractory to currently available therapies (N=32); t(1/2) was not affected. Capmatinib 400 mg twice daily for 12 days was coadministered with a single dose of digoxin 0.25 mg and rosuvastatin 10 mg on day 12 .
B) During drug interaction studies, administration of a single dose of rosuvastatin 10 mg to patients receiving capmatinib (400 mg twice daily) resulted in 2.08-fold increase in the AUC and 3.04-fold increase in the Cmax of rosuvastatin .
Capmatinib Overview
-
Capmatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Capmatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.
Sulfasalazine Overview
-
Sulfasalazine is used to treat ulcerative colitis (a condition which causes swelling and sores in the lining of the colon [large intestine] and rectum) and also to maintain improvement of ulcerative colitis symptoms. Sulfasalazine delayed-release (Azulfidine EN-tabs) is also used to treat rheumatoid arthritis in adults whose disease has not responded well to other medications or could not be tolerated. Sulfasalazine delayed-release (Azulfidine EN-tabs) is also used to treat polyarticular juvenile idiopathic arthritis (PJIA; a type of childhood arthritis that affects five or more joints during the first six months of the condition, causing pain, swelling, and loss of function) in children who have not been helped by other medications. Sulfasalazine is in a class of medications called anti-inflammatory drugs. It works by reducing inflammation (swelling) inside the body.
Return To Our Drug Interaction Homepage
Feedback, Question Or Comment About This Information?
Ask Dr. Brian Staiger, PharmD, our medical editor, directly! He's always more than happy to assist.
Definitions
Severity Categories
Contraindicated
These drugs, generally, should not be used together simultaneously due to the high risk of severe adverse effects. Combining these medications can lead to dangerous health outcomes and should be strictly avoided unless otherwise instructed by your provider.
Major
This interaction could result in very serious and potentially life-threatening consequences. If you are taking this drug combination, it is very important to be under close medical supervision to minimize severe side effects and ensure your safety. It may be necessary to change a medication or dosage to prevent harm.
Moderate
This interaction has the potential to worsen your medical condition or alter the effectiveness of your treatment. It's important that you are monitored closely and you potentially may need to make adjustments in your treatment plan or drug dosage to maintain optimal health.
Minor
While this interaction is unlikely to cause significant problems, it could intensify side effects or reduce the effectiveness of one or both medications. Monitoring for changes in symptoms and your condition is recommended, and adjustments may be made if needed to manage any increased or more pronounced side effects.
Onset
Rapid: Onset of drug interaction typically occurs within 24 hours of co-administration.
Delayed: Onset of drug interaction typically occurs more than 24 hours after co-administration.
Evidence
Level of documentation of the interaction.
Established: The interaction is documented and substantiated in peer-reviewed medical literature.
Theoretical: This interaction is not fully supported by current medical evidence or well-documented sources, but it is based on known drug mechanisms, drug effects, and other relevant information.
How To Manage The Interaction
Provides a detailed discussion on how patients and clinicians can approach the identified drug interaction as well as offers guidance on what to expect and strategies to potentially mitigate the effects of the interaction. This may include recommendations on adjusting medication dosages, altering the timing of drug administration, or closely monitoring for specific symptoms.
It's important to note that all medical situations are unique, and management approaches should be tailored to individual circumstances. Patients should always consult their healthcare provider for personalized advice and guidance on managing drug interactions effectively.
Mechanism Of Interaction
The theorized or clinically determined reason (i.e., mechanism) why the drug-drug interaction occurs.
Disclaimer: The information provided on this page is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional regarding your specific circumstances and medical conditions.
Where Does Our Information Come From?
Information for our drug interactions is compiled from several drug compendia, including:
The prescribing information for each drug, as published on DailyMED, is also used.
Individual drug-drug interaction detail pages contain references specific to that interaction. You can click on the reference number within brackets '[]' to see what reference was utilized.
The information posted is fact-checked by HelloPharmacist clinicians and reviewed quarterly.